Stoke Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ian F. Smith
- Full Time Employees
- 128
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 45 Wiggins Avenue Bedford MA United States of America 01730
- IPO Date
- Jun 19, 2019
- CIK
- 0001623526
- Website
- stoketherapeutics.com
- Similar Companies
- Business
- Stoke Therapeutics, Inc. Stoke Therapeutics, Inc. (Nasdaq: STOK) is a clinical-stage biotechnology company that develops RNA-based medicines to treat severe genetic diseases caused by haploinsufficiencies, using its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to upregulate protein expression from healthy genes via antisense oligonucleotides (ASOs). The company offers zorevunersen (STK-001), an investigational therapy in Phase 3 clinical trials for Dravet syndrome, a severe developmental epileptic encephalopathy; STK-002, in preclinical development for autosomal dominant optic atrophy (ADOA), the leading hereditary optic neuropathy; and additional pipeline programs targeting haploinsufficiency diseases of the central nervous system and eye. Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke Therapeutics operates primarily in the United States with a focus on rare neurological disorders affecting pediatric and adult patients. Recent developments include the launch of the global Phase 3 EMPEROR study for zorevunersen in 2025, supportive long-term clinical data from prior trials, advancement of its second TANGO program into the clinic for ADOA, a $165 million upfront license and collaboration agreement with Biogen Inc. Biogen Inc. in early 2025 for zorevunersen commercialization rights outside North America with eligibility for up to $385 million in milestones and royalties, and a partnership with Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals Inc. for novel RNA-based medicines in genetic neurodevelopmental diseases.
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.6% After Insider Selling
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)